Patented, Clinically Studied Anti-Inflammatory Supplement Predicted To Be New Leader In Joint Health Category
Green Bay, WI (September 7, 2005) – Terry Lemerond, the nutritional product innovator who introduced Glucosamine to North America, has discovered the next generation of joint health supplements: LitoZin®. Lemerond is proud to announce that the company he founded, EuroPharma, has secured the North American rights to this natural dietary supplement that clinical studies suggest could transform the lives of osteoarthritis patients.
LitoZin®, which is protected by both manufacturing and uses patents, has been shown to be safe and clinically effective in 82% of patients with effects seen in as little as three weeks. Numerous clinical studies over the last five years by recognized authorities in the fields of orthopedics, rheumatology, and cardiology have shown pain reduction and increased mobility, both critical to the quality of life for those who suffer from any form of arthritis. In addition, the ingestion of conventional pain-relieving medication decreased up to 100% in some participating subjects.
“LitoZin heralds the launch of the next generation of joint health supplements, with its impressive clinical results eclipsing the current category leader glucosamine” said Lemerond. “One of the largest long-term glucosamine studies showed only a 40% response rate to treatment and that it took up to 12 weeks before the subjects reported feeling improvement.” Additionally, a benefit of LitoZin not demonstrated in glucosamine studies is the reduction of pain medication consumption, a clear benefit given the increasing awareness of their side effects.
Lemerond, a well-known leader in natural product development, was the first supplement manufacturer to introduce the current category leader glucosamine sulfate to the US market in 1993 and is known for having extensive knowledge in the field of dietary supplements, particularly in the joint health category. Lemerond states “the scientific data on LitoZin is so impressive; it is far more effective than glucosamine. People are experiencing amazing results in symptom relief while using Litozin”.
“Lemerond and his management team have accomplished great success in the past with glucosamine. We at Hyben Vital are convinced, based on Lemerond’s history in the dietary supplement industry, that EuroPharma is the company of choice for Litozin in the North American market. We are proud to be aligned with EuroPharma.“ said Torbjorn Hansen, president of Hyben Vital, the Danish company that discovered and developed Litozin.
Glucosamine and LitoZin have very different mechanisms of action. While glucosamine has been clinically shown to build joint cartilage, it does not have any anti-inflammatory properties. On the other hand, LitoZin contains a galactolipid compound, called GOPO™, that has proven to be an active anti-inflammatory compound.
GOPO™ content varies considerably in different species of rose hip. Through years of analysis, Hyben Vital determined that the most effective rose hip contained an extremely high content of GOPO. They were then able to produce a unique sub-species of the rose hip plant with the highest content of GOPO.
Hyben Vital then developed a proprietary drying process to ensure the active component is present in the finished product. Other rose hip products contain little or no GOPO in their raw state, furthermore conventional processing, even sun-drying, destroys this essential constituent. Thus, commonly available rose hip products will not result in the same benefits as have been illustrated in the scientific evaluation of Litozin®. The GOPO™ compound and its anti-inflammatory use is patented in both North America and Europe.
LitoZin is virtually free of all side effects that are commonly associated with conventional pain medications. In contrast to NSAID’s and aspirin LitoZin does not interfere with the body’s blood clotting mechanism. This is extremely important for those taking medications for cardiovascular conditions – many of which also suffer from arthritis. In addition, Litozin has been clinically shown to lower C-reactive protein levels, an inflammatory marker associated with cardiovascular risk.
To date a total of 13 chemical, pharmacological and clinical studies have been completed and additional studies are ongoing. The latest study was recently published in the August 2005 issue of the Scandinavian Journal of Rheumatology.
Swanson Health Products, a family owned and operated company based in Fargo, North Dakota and one of America's largest privately held mail-order and internet marketers of dietary supplements, will be launching LitoZin in September. For more information visit www.swansonvitamins.com.
EuroPharma is seeking other companies to launch the product in additional distribution channels.
Located in Green Bay, Wisconsin, EuroPharma, Inc., is committed to discovering innovative products that have been extensively researched and demonstrated to be safe, natural and effective which will help people live healthier and more fulfilling lives. EuroPharma’s mission is to bring truly unique and industry changing products to the U.S. marketplace. EuroPharma is an extension of its founder, Terry Lemerond’s historic successes and a proven model of product development. For more information, visit www.EuroPharmaUSA.com.
- END –